Alnylam Pharmaceuticals (NASDAQ:ALNY) is a biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to the discovery, development and commercialization of novel therapeutics based on ribonucleic acid (RNA) interference (RNAi). Since its founding in 2002, Alnylam has pursued RNAi as a breakthrough approach for addressing the root cause of diseases by silencing specific genes involved in disease pathogenesis. The company’s platform integrates advanced lipid nanoparticle delivery systems and proprietary GalNAc conjugate chemistry to enable the efficient and selective delivery of RNAi therapeutics to target tissues.
Alnylam has brought multiple RNAi-based medicines to market, focusing primarily on rare genetic diseases. Its first approved product, ONPATTRO® (patisiran), targets transthyretin-mediated amyloidosis and has set the standard for RNAi therapy in polyneuropathy patients. Following that success, Alnylam introduced GIVLAARI® (givosiran) for acute hepatic porphyria, and OXLUMO® (lumasiran) for primary hyperoxaluria type 1. The company’s growing portfolio also includes AMVUTTRA® (vutrisiran) for hereditary ATTR amyloidosis and a robust pipeline of investigational candidates addressing conditions such as hypercholesterolemia, cardiomyopathy and other liver- or central nervous system–related disorders.
With a global footprint, Alnylam maintains operations across North America, Europe and Asia Pacific, supporting clinical development, manufacturing and commercialization efforts. Its strategic collaborations and partnerships extend to academic institutions, biotech firms and pharmaceutical companies to accelerate the translation of its RNAi platform into new therapeutic modalities. Alnylam’s manufacturing network leverages both internal facilities and contract development and manufacturing organizations to ensure scalability and quality control for its lipid nanoparticle and conjugate-based products.
Alnylam is led by President and Chief Executive Officer Yvonne Greenstreet, who brought extensive experience in global pharmaceuticals and biopharmaceutical leadership to the company in mid-2021. Under her stewardship, the company continues to expand its commercial presence while advancing late-stage programs in cardiometabolic and central nervous system indications. Backed by a seasoned executive team and a scientific advisory board featuring pioneers in RNA biology, Alnylam remains at the forefront of translating gene-silencing science into meaningful treatments for patients with serious and life-threatening diseases.
